BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.01% | 125.05% | -154.18% | -169.39% | 182.02% |
| Total Depreciation and Amortization | 261.20% | -9.12% | 29.18% | -50.99% | 88.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.84% | -1,185.11% | 107.31% | -301.83% | 531.79% |
| Change in Net Operating Assets | 0.60% | -129.16% | 954.18% | 22.74% | -71.72% |
| Cash from Operations | 29.69% | -140.10% | 608.46% | -137.60% | 3.75% |
| Capital Expenditure | 11.30% | 16.07% | -50.16% | 29.52% | -53.31% |
| Sale of Property, Plant, and Equipment | 126.26% | 53.18% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,037.01% | 53.54% | 93.25% | 13.28% | -207.02% |
| Cash from Investing | 513.98% | 39.87% | 89.61% | 13.78% | -116.34% |
| Total Debt Issued | -- | -- | -- | -- | 100.00% |
| Total Debt Repaid | 7.59% | 65.50% | -193.59% | 36.59% | -30.85% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 99.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.40% | 64.76% | -191.09% | 39.03% | 95.90% |
| Foreign Exchange rate Adjustments | 673.33% | 28.81% | -148.12% | 104.90% | -325.95% |
| Miscellaneous Cash Flow Adjustments | -130.75% | -1.39% | 162.35% | -139.40% | -- |
| Net Change in Cash | 117.70% | -154.87% | 151.66% | -47.89% | -170.15% |